Abstracts tagged "rheumatoid arthritis"

Abstract Number: 593 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up
Sebastian C Rodriguez-Garcia¹, Raul Castellanos-Moreira Sr.¹, José Inciarte-Mundo², M. Victoria Hernández³, Virginia Ruiz-Esquide², Andrea Cuervo¹, Julio Ramírez², Juan Cañete¹, Jose Gomez Puerta¹ and Raimon Sanmartí¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain
Background/Purpose: Recommendations and guidelines for the management of Rheumatoid Arthritis (RA) and spondyloarthritis (SpA) with bDMARD include dose-tapering as an adequate option for patients on…
Abstract Number: 2461 • 2018 ACR/ARHP Annual Meeting
Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Pia Mercedes Lois¹, Cristina Vadillo Font¹, Dalifer Freites Núñez², Isabel Hernández-Rodríguez¹, Juan A Jover Jover¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the Disease Modifying Drugs (DMARD) widely used.…
Abstract Number: 603 • 2018 ACR/ARHP Annual Meeting
Rheumatologists Beliefs in the Effectiveness of Other Methotrexate-Based Treatment Approaches May Explain the Low Use of Triple Therapy: A Bayesian Belief Elicitation
Gyanendra Pokharel¹, Rob Deardon¹, Sindhu Johnson², George A. Tomlinson³ and Glen Hazlewood⁴, ¹Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, ²Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Triple therapy (MTX, sulphasalazine (SSZ), hydroxychloroquine (HCQ)) has evidence to support its use from randomized trials (RCTs) but is not commonly used. The objective…
Abstract Number: 2522 • 2018 ACR/ARHP Annual Meeting
Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)
Stanley Cohen¹, Niklas Czeloth², Eric Lee³, Piotr A. Klimiuk⁴, Nuala Peter⁵ and Girish Jayadeva², ¹Metroplex Clinical Research Center, Dallas, TX, ²Boehringer Ingelheim, Ingelheim a.R., Germany, Ingelheim, Germany, ³Inland Rheumatology, Upland, CA, ⁴Medical University of Bialystok and Gabinet Internistyczno-Reumatologiczny, Bialystok, Poland, ⁵Boehringer Ingelheim, Biberach a.d.R., Germany, Ingelheim a.R., Germany
Background/Purpose: Clinical equivalence of BI 695501 to the adalimumab RP has been shown in pts with moderately-to-severely active RA in the Phase III VOLTAIRE®-RA study…
Abstract Number: 628 • 2018 ACR/ARHP Annual Meeting
Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database
Elliot Hepworth¹, Mohammad Movahedi², Emmanouil Rampakakis³, Reza Mirza¹, Arthur Lau⁴, Angela Cesta⁵, Janet E. Pope⁶ and Claire Bombardier⁷, ¹Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴50 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next…
Abstract Number: 2898 • 2018 ACR/ARHP Annual Meeting
Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)
Paula Fortea-Gordo¹, Laura Nuño², Alejandro Villalba², Diana Peiteado³, Irene Monjo⁴, Paloma Sanchez-Mateos⁵, Amaya Puig-Kröger⁶, Alejandro Balsa¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Immunology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: A novel population of CD4+ T cells with B cell helping capacity has been described in the synovial tissues and peripheral blood of seropositive…
Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan
Song-Chou Hsieh¹, Yi-Hsing Chen², Wei-Sheng Chen³, Wen-Chan Tsai⁴, Jui-Chieh Hu⁵, Hsiang-Cheng Chen⁶, Jack Mardekian⁷ and Chacun Lai⁸, ¹National Taiwan University Hospital, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung City, Taiwan, ³Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, ⁷Pfizer Global Biometrics & Data Management, NY, NY, ⁸Pfizer PFE Limited, New Taipei, Taiwan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting
Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
Judith Ashouri¹, Lih-Yun Hsu¹, Dmitry Rychkov², Marina Sirota², Lisa Lattanza³, Eric Hansen³, Julie Zikherman¹ and Arthur Weiss¹, ¹Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ³Orthopedic Surgery, University of California, San Francisco, San Francisco, CA
Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting
Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
Caitrin Coffey¹, Michael Richter¹, Cynthia S. Crowson², Matthew J. Koster³, Kenneth J. Warrington⁴ and Ashima Makol³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
Stanley Cohen¹, Yoshiya Tanaka², Xavier Mariette³, Jeffrey R. Curtis⁴, Eun Bong Lee⁵, Peter Nash⁶, Kevin Winthrop⁷, Christina Charles-Schoeman⁸, Lisy Wang⁹, Connie Chen¹⁰, Kenneth Kwok¹⁰, Pinaki Biswas¹⁰, Andrea Shapiro¹¹, Ann Madsen¹⁰ and Jürgen Wollenhaupt¹², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Paris-Sud University, Le Kremlin Bicêtre, France, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Seoul National University, Seoul, Korea, Republic of (South), ⁶University of Queensland, Brisbane, Australia, ⁷Oregon Health and Science University, Portland, OR, ⁸University of California, Los Angeles, CA, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Peapack, NJ, ¹²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…
Abstract Number: 395 • 2017 ACR/ARHP Annual Meeting
Pharmacological and Safety Profiles of Cyclin-Dependent Kinase 4/6 Inhibitor, Candidate for Development As Rheumatoid Arthritis Therapeutic Option
Johji Nomura¹, Shunsuke Tsujimoto², Kei Tamura², Wataru Yamamoto², Hiroshi Takahashi², Kyohei Horie², Toshiya Mashiko², Naoki Hase² and Tsunefumi Kobayashi², ¹Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan, ²TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the excessive proliferation of synovial…
Abstract Number: 396 • 2017 ACR/ARHP Annual Meeting
Phospho-STAT1 Inhibition Is the Initial Step after Tofacitinib Treatment in Rabbits with Severe Chronic Synovitis
Sandra Pérez-Baos, Paula Gratal, Juan Ignacio Barrasa, Ana Lamuedra, Gabriel Herrero-Beaumont and Raquel Largo, Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Tofacitinib (TOFA) is a Janus Kinase (Jak) inhibitor approved for the treatment of rheumatoid arthritis (RA) 1. It has recently been shown to selectively…
Abstract Number: 398 • 2017 ACR/ARHP Annual Meeting
An on-Demand Drug Delivery System for the Treatment of Inflammatory Arthritis
Jing Yan¹, Nitin Joshi², Seth Levy², Sachin Bhagchandani², Kai Slaughter², Nicholas Sherman¹, Julian Amirault², Xueyin He², Tan Shi Rui², Michael Valic², Praveen Vemula³, Oscar Miranda², Oren Levy², Antonios Aliprantis⁴, Joerg Ermann¹ and Jeffrey Karp², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Institute for Stem Cell Biology and Regenerative Medicine (inStem), Bangalore, India, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Many types of inflammatory arthritis (IA) are treated with systemic therapy. In situations where only one or a few joints are active, intra-articular drug…
Abstract Number: 417 • 2017 ACR/ARHP Annual Meeting
Improvement in Overall Work Productivity Among Biologic-NaïVe Patients with Rheumatoid Arthritis Treated with Tocilizumab Subcutaneous Injection: A Prospective, Real World, Observational Study in Japan
Yoshiya Tanaka¹, Hideto Kameda², Kazuyoshi Saito³, Yuko Kaneko⁴, Eiichi Tanaka⁵, Shinsuke Yasuda⁶, Naoto Tamura⁷, Keishi Fujio⁸, Takao Fujii⁹, Toshihisa Kojima¹⁰, Tatsuhiko Anzai¹¹, Chikuma Hamada¹², Yoshihisa Fujino¹³, Shinya Matsuda¹³ and Hitoshi Kohsaka¹⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, ³Tobata General Hospital, Fukuoka, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ⁷Department of Internal Medicine and Rheumatology, Juntedo University School of Medicine, Tokyo, Japan, ⁸Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ⁹Department of Rheumatism and Collagen Disease, Wakayama Medical University, Wakayama, Japan, ¹⁰Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, ¹¹Data Science Division, Statistics Analysis Department 1, EPS Corporation, Tokyo, Japan, ¹²Department of Information and Computer Technology, Tokyo University of Science, Tokyo, Japan, ¹³Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁴Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: This is the first study assessing the effect of subcutaneous tocilizumab (TCZ-SC) and/or conventional synthetic DMARDs (csDMARDs) on work productivity and activity impairment (WPAI)…
Abstract Number: 536 • 2017 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen Cohort
Ruediger Mueller¹, Frederik Mattow², Florian Popp³ and Johannes von Kempis⁴, ¹Division of Rheumatology, Cantonal Hospital, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Rorschacherstrasse 95, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Efficacy and safety of tofacitinib have been shown in several clinical studies. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].